Self-reported occupational functioning in persons with relapsing-remitting multiple sclerosis: Does personality matter?
نویسندگان
چکیده
BackgroundMultiple sclerosis (MS) poses a major threat to sustainable employability. Identifying conditions and factors that promote work participation is of great importance. Our objective was explore the contribution personality traits in explaining occupational functioning MS.Methods241 participants with relapsing-remitting MS (78% female, median age: 42.0 years, EDSS: 2.0) 60 healthy controls (70% 45.0 years) underwent neuropsychological neurological examinations completed questionnaires. Multivariate logistic linear regression analyses were conducted examine relations between self-reported functioning, while accounting for known correlates.ResultsPersonality not associated when correcting correlates. A higher impact fatigue (B = -0.05, p .005 B -0.04, .009) depression -0.22, .008 -0.21, .01) no paid job (R2 0.13) considering reduce hours 0.12). .008, ? 0.46, .001 ?0.36, .001) absenteeism from 0.15), more presenteeism 0.35) lower ability 0.25). (? anxiety 0.25, difficulties 0.54).ConclusionPersonality did explain additional variance persons mild disability. The main most consistent correlate often combined or anxiety. Total explained models limited, emphasizing need additionally other (contextual) challenges MS.
منابع مشابه
Does Self-Efficacy Affect Cognitive Performance in Persons with Clinically Isolated Syndrome and Early Relapsing Remitting Multiple Sclerosis?
In persons with multiple sclerosis (MS) a lowered self-efficacy negatively affects physical activities. Against this background we studied the relationship between self-efficacy and cognitive performance in the early stages of MS. Thirty-three patients with Clinically Isolated Syndrome (CIS) and early Relapsing Remitting MS (eRRMS) were assessed for self-efficacy (MSSES-18), cognition (CDR Syst...
متن کاملSafety and Efficacy of Fingolimod in Iranian Patients with Relapsing-remitting Multiple Sclerosis
Introduction: Fingolimod is the first confirmed oral immune-modulator to treat Relapsing-Remitting Multiple Sclerosis (RRMS). This study aimed to investigate the safety and efficacy of fingolimod therapy in Iranian patients with RRMS. Methods: In our trial, 50 patients resistant to conventional interferon therapy were assigned to receive fingolimod 0.5 mg per day for 12 months. The number of D...
متن کاملInterferons in relapsing remitting multiple sclerosis.
BACKGROUND Recombinant interferons have been shown to suppress both the clinical and magnetic resonance imaging (MRI) measures of disease activity in patients with relapsing remitting multiple sclerosis (RRMS). OBJECTIVES We performed a Cochrane review of all randomised, placebo-controlled trials of recombinant interferons in RRMS. SEARCH STRATEGY Of 208 articles identified by a predefined ...
متن کاملThalamic neurodegeneration in relapsing-remitting multiple sclerosis.
OBJECTIVE To define the extent of neuronal injury and loss in thalamic gray matter in patients with relapsing-remitting (RR) MS and to characterize how these neuronal pathologic changes are related to disease duration. METHODS The authors studied 14 patients with RRMS (Expanded Disability Status Scale score, mean 3.25, range 2.0 to 6.0) and 14 (8 men, 6 women) age-matched healthy controls. St...
متن کاملNatalizumab in relapsing-remitting multiple sclerosis.
Natalizumab is the first humanized moclonal antibody indicated in the treatment of relapsing-remitting multiple sclerosis (RRMS). Based on its remarkable efficacy in reducing disease activity and reducing the risk of disability progession in RRMS, and the risk of a serious adverse event (progressive multifocal leukoencephalopathy [PML]), natalizumab was indicated in active RRMS, mostly as a sec...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Journal of the Neurological Sciences
سال: 2021
ISSN: ['0022-510X', '1878-5883']
DOI: https://doi.org/10.1016/j.jns.2021.117561